Stock analysts at Leerink Partners assumed coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) in a report issued on Tuesday, Zacks reports. The firm set a “strong-buy” rating on the stock.
Other equities research analysts have also issued research reports about the stock. Guggenheim assumed coverage on shares of Retension Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $55.00 target price on the stock. Oppenheimer initiated coverage on shares of Retension Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $50.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat.com, Retension Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $52.50.
Check Out Our Latest Stock Analysis on Retension Pharmaceuticals
Retension Pharmaceuticals Price Performance
Retension Pharmaceuticals stock opened at $11.60 on Tuesday. Retension Pharmaceuticals has a 1-year low of $9.66 and a 1-year high of $18.64.
Insider Buying and Selling at Retension Pharmaceuticals
In other news, CEO Eric L. Keller purchased 20,800 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $249,600.00. Following the completion of the acquisition, the chief executive officer owned 423,377 shares in the company, valued at $5,080,524. This trade represents a 5.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Franklin M. Berger acquired 10,000 shares of Retension Pharmaceuticals stock in a transaction on Tuesday, October 13th. The stock was purchased at an average cost of $12.00 per share, with a total value of $120,000.00. Following the completion of the transaction, the director directly owned 10,000 shares in the company, valued at $120,000. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing.
About Retension Pharmaceuticals
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
Recommended Stories
- Five stocks we like better than Retension Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
